Xeris Biopharma Holdings

Company snapshot

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

• 1 approved product(s) across US/EU regulatory metadata.
• 16 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Xeris Biopharma Holdings. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Xeris Biopharma Holdings.

1. Jun 8, 2026 Clinical update

   Novo Nordisk GlucaGen® — Phase 2

2. Jun 8, 2026 Clinical update

   levothyroxine sodium — Phase 2

3. Jun 8, 2026 Clinical update

   Glucagon RTU Injection With Insulin Pump Reduction — Phase 2

4. Jun 8, 2026 Clinical update

   Glucagon RTU — Phase 2

5. Jun 8, 2026 Clinical update

   Glucagon — Phase 2

View all clinical trial activity →

• What is Xeris Biopharma Holdings?

  Xeris Biopharma Holdings is a biotech organization headquartered in Chicago, USA. It trades on NYSE under ticker XERS. Primary therapeutic focus areas include Hypoglycemia, Diabetes Mellitus, Type 1, Insulin Hypoglycemia, Congenital Hyperinsulinism, Post-bariatric Hypoglycemia. N

• Is Xeris Biopharma Holdings publicly traded?

  Yes. Xeris Biopharma Holdings is listed with ticker XERS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Xeris Biopharma Holdings develop or market?

  We link 12 drug profile(s) where Xeris Biopharma Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xeris-biopharma-holdings#company-drugs.

• What are the latest developments for Xeris Biopharma Holdings?

  In the last 12 months our linked public records show 16 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Xeris Biopharma Holdings focus on?

  Xeris Biopharma Holdings focuses on Hypoglycemia, Diabetes Mellitus, Type 1, Insulin Hypoglycemia based on our analysis of their pipeline programs and drug development activities.